Evoke Pharma Inc (EVOK)

NASDAQ

Currency in USD

3.8500

-0.1000(-2.53%)

Closed·30/07

After Hours

3.8100-0.0400(-1.04%)

·30/07

Fair Value

Unlock Value

Day's Range

3.7110

3.9600

52 wk Range

1.9400

12.3199

EVOK Financial Summary

A brief financial summary of Evoke Pharma Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-1.71

Price/Book1.28

Debt / Equity88.08%

Return on Equity-108.77%

Dividend Yield0.00%

EBITDA0.00

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

0.02

1.62

2.51

5.18

10.25

Gross Profit

aa.aa

-0.06

1.29

2.14

4.98

9.89

Operating Income

aa.aa

-13.05

-8.15

-7.79

-7.43

-5.2

Net Income

aa.aa

-13.15

-8.54

-8.22

-7.79

-5.35

Balance Sheet

Total Assets

aa.aa

9.43

10.57

11.85

7.07

17.52

Total Current Liabilities

aa.aa

7.54

1.41

1.65

9.65

10.38

Total Equity

aa.aa

-3.21

3.56

4.08

-2.58

7.04

Cash Flow

Levered Free Cash Flow

aa.aa

-1.81

-9.63

-4.05

-0.91

-3.67

Cash from Operations

aa.aa

-6.63

-12.35

-6.6

-4.98

-5.46

Cash from Investing

aa.aa

Cash from Financing

aa.aa

9.04

13.43

7.29

-0.12

14.32

Net Change in Cash

aa.aa

2.41

1.08

0.7

-5.1

8.86

* In Millions of USD (except for per share items)

Analyst Ratings

1 Buy

0 Hold

0 Sell

Ratings:

1 analysts

Overall Consensus

Buy

Analysts 12-Month Price Target:

Average 18.0000

(+367.53% Upside)

Earnings

Latest Release

May 13, 2025

EPS / Forecast

-0.51 / --

Revenue / Forecast

3.08M / 3.32M

EPS Revisions

Unlock

Last 90 days

FAQ

What were Evoke Pharma's earnings for the latest quarter?

The Evoke Pharma EPS (TTM) is -2.16. Evoke Pharma reported sales of 3.08, net income of -1.31, and EPS of -0.51 for the latest quarter.

What was Evoke Pharma's net income for the latest quarter?

Evoke Pharma's net income for the latest quarter was -1.31.

How did Evoke Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 3.31 in the previous quarter to 3.08 in the latest quarter, and net income moved from -1.19 to -1.31 compared to the previous quarter.

What is Evoke Pharma's net profit margin on a TTM basis?

Evoke Pharma's trailing twelve months (TTM) net profit margin is -52.22%.

How does Evoke Pharma's debt to equity ratio compare to industry standards?

Evoke Pharma's total debt-to-equity ratio is 88.08%.

What is Evoke Pharma's return on investment on a TTM basis?

Evoke Pharma's trailing twelve months (TTM) return on investment (ROI) is -108.77%.

Did Evoke Pharma gain or lose cash last quarter?

In the latest quarter, Evoke Pharma's net change in cash was -0.97 million.

What were Evoke Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Evoke Pharma reported total assets of 16.38 million and total liabilities of 10.45 million.

How has Evoke Pharma's total revenue grown this year?

Evoke Pharma's total revenue was 3.31 in the previous quarter and 3.08 in the latest quarter.

What is Evoke Pharma's gross margin on a TTM basis?

Evoke Pharma's trailing twelve months (TTM) gross margin is 97.36%.

What was Evoke Pharma's revenue per share for the latest quarter?

Evoke Pharma's revenue per share for the latest quarter was 43.97.

NSE 30

5,110.26

+51.12

+1.01%

NSE All Share

139,278.67

+1,365.80

+0.99%

US 30

44,599.30

+138.0

+0.31%

US 500

6,423.20

+60.3

+0.95%

FTSE 100

9,136.94

+0.62

+0.01%

DAX

24,262.22

+44.85

+0.19%

South Africa Top 40

91,597.63

+76.89

+0.08%

Market Movers

Name	Last	Chg. %	Vol.
Fidelitybk	21.000	+2.44%	90.40M
Guaranty Trust Holding	101.95	+4.03%	30.26M
Nigerian Breweries	77.00	+4.05%	29.34M
Nascon	99.90	+8.59%	16.82M
Lafarge Africa	151.00	+7.63%	14.59M
MTN Nigeria	471.10	+4.32%	6.99M
Dangote Cement	509.60	0.00%	3.59M

Name	Last	Chg. %	Vol.
Multverse	9.90	+10.00%	843.76K
Royalex	1.54	+10.00%	25.12M
Npfmcrfbk	3.420	+9.97%	11.86M
Dangote Sugar	71.15	+9.97%	7.69M
Berger Paints	37.50	+9.97%	2.92M
UAC Of Nigeria	73.00	+9.94%	2.99M
Mecure Industries	14.45	+9.89%	2.18M

Name	Last	Chg. %	Vol.
FTN Cocoa Processors PLC	6.30	-10.00%	13.97M
Abbey Mortgage Bank	6.48	-10.00%	754.65K
Livingtrust Mortgage Bank	6.59	-9.97%	103.95K
Sunu Assurances	4.14	-9.61%	11.72M
Consolidated Hallmark	3.20	-7.78%	10.38M
Honeywell Flour Mills Plc	25.050	-7.22%	13.78M
Tantalizers	2.51	-7.04%	4.98M

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	471.10	+4.32%	6.99M
Guaranty Trust Holding	101.95	+4.03%	30.26M
Okomu Oil Palm	1,050.00	0.00%	385.41K
Lafarge Africa	151.00	+7.63%	14.59M
Access Holdings	27.60	+1.47%	43.05M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A Aaa Aa	509.60	+38.81%	707.38
A Aaaaaa Aaaaaaaaaa	5,450.00	+30.99%	7,138.95
Aaaaaaa Aaa Aaa A A	66.50	+25.53%	83.48
Aaaaaaaaaa	135.00	+24.29%	167.79

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Evoke Pharma Inc (EVOK)

EVOK Financial Summary

Key Ratios

Statements Highlights

Analyst Ratings

Analysts 12-Month Price Target:

Earnings

FAQ

What were Evoke Pharma's earnings for the latest quarter?

What was Evoke Pharma's net income for the latest quarter?

How did Evoke Pharma's performance compare year-over-year in the latest quarter?

What is Evoke Pharma's net profit margin on a TTM basis?

How does Evoke Pharma's debt to equity ratio compare to industry standards?

What is Evoke Pharma's return on investment on a TTM basis?

Did Evoke Pharma gain or lose cash last quarter?

What were Evoke Pharma's total assets and liabilities in the latest quarter?

How has Evoke Pharma's total revenue grown this year?

What is Evoke Pharma's gross margin on a TTM basis?

What was Evoke Pharma's revenue per share for the latest quarter?

Trending Stocks